F.D.A. Warns Supplement Makers to Stop Touting Cures for Diseases Like Alzheimer ’ s
The agency warned 12 dietary supplement companies to stop marketing such products for disease treatments, and called for tougher regulation of the $40 billon industry.
CONCLUSION: Our results indicate that values of surface tension are not a suitable biomarker for AD. However, the ratio of ThioflavinT-based fluorescence to intrinsic amyloid fluorescence in cerebrospinal fluid appears to be an acceptable supportive diagnostic biomarker for AD (its sensitivity was 61.1%, and the specificity 70.8% when compared with aged controls). PMID: 30888831 [PubMed - as supplied by publisher]
Abstract Falls are a major health care concern in individuals with Alzheimer disease (AD) and their caregivers. Vestibular impairment is a known risk factor for falls, and individuals with AD have been shown to have an increased prevalence of vestibular loss compared with age-matched controls. Vestibular physical therapy (VPT) is effective in improving balance and reducing fall risk in cognitively-intact persons with vestibular impairment. However, the effectiveness of VPT in improving balance and reducing falls in individuals with AD who have vestibular loss has never been explored. SUMMARY OF KEY POINTS:: In thi...
Research ArticlesMarco Cavallo, Enrico Zanalda, Harriet Johnston, Alessandro Bonansea, Chiara Angilletta,Brain Impairment,Volume 17 Issue 02, pp 182-192Abstract
Publication date: Available online 19 March 2019Source: NeuroImage: ClinicalAuthor(s): Ellen Dicks, Lisa Vermunt, Wiesje M. van der Flier, Pieter Jelle Visser, Frederik Barkhof, Philip Scheltens, Betty M. Tijms, for the Alzheimer's Disease Neuroimaging InitiativeAbstractBackgroundGrey matter (GM) atrophy in Alzheimer's disease (AD) is most commonly modeled as a function of time. However, this approach does not take into account inter-individual differences in initial disease severity or changes due to aging. Here, we modeled GM atrophy within individuals across the AD clinical spectrum as a function of time, aging and MMSE...
Condition: Alzheimer Disease Interventions: Device: Transcranial Alternating Current Stimulation (tACS); Other: Sham Transcranial Alternating Current Stimulation Sponsors: Beth Israel Deaconess Medical Center; Massachusetts General Hospital; National Institutes of Health (NIH) Not yet recruiting
(MedPage Today) -- News and commentary from the world of neurology and neuroscience
New evidence suggests that a combined light and sound stimulation therapy could boost brain health and improve the symptoms of Alzheimer's disease.
The Academy for Health and Lifespan Research was recently announced, an initiative analogous to that of the long-running Longevity Dividend group, but hopefully more energetic and more focused on at least some rejuvenation biotechnologies such as senolytic therapies. The principals include many of the researchers now involved in startup biotech companies working on ways to intervene in the mechanisms of aging, and the goal is to generate greater support for development of means to slow or reverse aging and age-related disease. David Sinclair is associated with Life Biosciences and its collection of portfolio companies, and...
By analyzing the white-matter connections of an infant's brain at birth on...Read more on AuntMinnie.comRelated Reading: PET, AI show women's brains age differently than men's Machine learning, fMRI unlock cellular brain properties AI, diffusion MRI can predict outcomes for epilepsy AI helps uncover clues for Alzheimer's disease in MRI data NYMIIS: Next-gen PACS will include 'best-of-breed' AI